Tanji Patton Shared Breast Cancer Treatment Update
The television host will undergo endocrine therapy for her breast cancer diagnosis in Houston.
Updated on Oct. 5, 2026 in Cancer
Tanji Patton, who launched the Goodtaste brand in 2008, revealed in July 2026 that she received a breast cancer diagnosis. She is currently undergoing treatment at the MD Anderson Cancer Center in Houston.
Why it matters
Understanding treatment pathways is essential for patients, as clinical decisions often shift based on specific diagnostic markers. Patton is moving forward with endocrine therapy rather than chemotherapy or radiation following her surgical interventions.
Patton is utilizing endocrine therapy as her primary medical approach following surgical procedures at the MD Anderson Cancer Center. The clinical strategy specifically excludes the use of chemotherapy and radiation therapy for her current condition.
The players
Tanji Patton
A television personality and brand founder who previously worked at News 4 San Antonio for 17 years.
MD Anderson Cancer Center
A Houston-based comprehensive cancer center providing specialized, multidisciplinary oncological care.
The details
Endocrine therapy works by blocking hormones or preventing their production to slow the growth of hormone receptor-positive breast cancer cells. By focusing on these systemic hormone interactions, physicians can sometimes bypass the need for more aggressive cytotoxic therapies like chemotherapy or tissue-damaging radiation. Patients at centers like MD Anderson often receive tailored plans that prioritize these targeted approaches when clinical markers suggest a favorable response to endocrine agents.
Timeline
Patton launched her online brand in 2008.
The television series debuted in 2016.
The breast cancer diagnosis was revealed in July 2026.
Patton recounted an interaction with a fellow patient on September 26, 2026.
The update regarding her endocrine therapy plan was shared on October 5, 2026.
Health Landscape
The trend in modern oncology increasingly emphasizes de-escalating therapy by using targeted endocrine treatments instead of broad-spectrum chemotherapy whenever clinical markers permit. This approach follows established MD Anderson Cancer Center multidisciplinary oncology protocols designed to maximize patient quality of life.
Patients diagnosed with breast cancer should consult their medical team about whether targeted endocrine therapy might be an alternative to more invasive treatments. Discussing the specific role of your tumor's hormone receptor status is a key step in personalizing your own care plan.
The takeaway
Treatment plans are highly individualized based on the biological characteristics of the cancer. Patients should consistently track their diagnostic updates and maintain an open dialogue with their care team regarding the potential for targeted, less-intensive therapeutic options.
Further reading
Learn more about the latest standard-of-care developments for patients at Cancer.
